Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoXSWX:LLY 25 Cash-to-Debt is 0.16 as of Jun. 2026, which is 6% below its 10-year median of 0.17. GuruFocus rates XSWX:LLY with a GF Score™ of 25/100 and a GF Value™ of CHF1,164.75 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 983 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 80.57% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Eli Lilly and Co's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.16.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Eli Lilly and Cocouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Eli Lilly and Co's Cash-to-Debt or its related term are showing as below:
XSWX:LLY'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.17 Max: 0.72
Current: 0.16
During the past 13 years, Eli Lilly and Co's highest Cash to Debt Ratio was 0.72. The lowest was 0.08. And the median was 0.17.
XSWX:LLY's Cash-to-Debt is ranked worse than 80.57% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs XSWX:LLY: 0.16
Eli Lilly and Co (XSWX:LLY) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Eli Lilly and Co Cash-to-Debt Related Terms
Eli Lilly and Co Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:LLY vs JNJ, ABBV, MRK: Cash-to-Debt Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XSWX:LLY) has a Cash-to-Debt of 0.16 as of Jun. 2026. This is near median its historical median of 0.17. Over the past decade, Eli Lilly and Co's Cash-to-Debt has ranged from 0.08 to 0.72. According to the industry distribution chart, Eli Lilly and Co ranks #792 out of 983 companies in the Drug Manufacturers industry, placing it in the top 80.6%.
Is Eli Lilly and Co's Cash-to-Debt too high?
Eli Lilly and Co's current Cash-to-Debt of 0.16 is near median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.72. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Eli Lilly and Co's value of 0.16 is 83.7% below this industry median. Based on the distribution chart, Eli Lilly and Co ranks #792 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 25/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Cash-to-Debt compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #792 out of 983 companies for Cash-to-Debt. This places Eli Lilly and Co in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Eli Lilly and Co's value of 0.16 is 83.7% below this benchmark. Historically, Eli Lilly and Co's own Cash-to-Debt has ranged from 0.08 to 0.72 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 0.98, Eli Lilly and Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Cash-to-Debt of 0.16 is 83.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Cash-to-Debt is 0.16, which is near median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,164.75, compared to a current price of CHF955.00 — trading 18% below its estimated fair value. The current Cash-to-Debt is 0.16, which is near median its 10-year median of 0.17 and 83.7% below the Drug Manufacturers industry median of 0.98. Eli Lilly and Co's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Cash-to-Debt is 0.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF955.00 is trading 18% below its estimated GF Value™ of CHF1,164.75.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Cash-to-Debt: 0.16 (near median its 10-year median of 0.17)
GF Value™: CHF1,164.75 vs. price of CHF955.00 (18% below fair value)
Industry Position: 83.7% below the Drug Manufacturers median (#792 of 983)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
25GF Score
Get the complete analysis for XSWX:LLY
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
